



Study shows life-saving benefit of baricitinib for ventilated COVID patients

February 8 2022, by Craig Boerner



**Number at risk
(number of events
between timepoints)**

Placebo plus standard of care group	50 (11)	39 (10)	28 (7)	20 (1)	19 (0)
Baricitinib plus standard of care group	51 (3)	47 (8)	38 (6)	32 (3)	29 (0)



**Number at risk
(number of events
between timepoints)**

Placebo plus standard of care group	50 (11)	39 (10)	28 (7)	20 (1)	19 (2)	16 (0)
Baricitinib plus standard of care group	51 (3)	48 (8)	40 (6)	34 (3)	31 (3)	25 (0)

Kaplan-Meier estimates of all-cause mortality by day 28 and by day 60 (A) 28-day all-cause mortality. (B) 60-day all-cause mortality. All-cause mortality includes deaths potentially related with COVID-19 and deaths attributed to adverse events. The numbers at risk at days 27 and 59 represent the numbers of participants with available data at days 28 and 60, respectively. The data in parentheses below the curve represent the numbers of deaths that occurred during the interval until the next timepoint. HRs and 95% CIs were calculated using a Cox proportional hazard regression model adjusted for treatment group, age (

Citation: Study shows life-saving benefit of baricitinib for ventilated COVID patients (2022, February 8) retrieved 28 July 2024 from <https://medicalxpress.com/news/2022-02-life-saving-benefit-baricitinib-ventilated-covid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.